Results: Among forty-five patients, 33 had loss while 12 had intact SMAD4. Loss of SMAD4 carries a 1.3 times increased risk of vascular and 1.6 times risk of nodal spread. Deletion of SMAD4 was associated with poor differentiation (p=0.04,OR=5.6,C.I=0.9-34.4), and increased the risk of perineural invasion by two times (OR=2,C.I=0.1-34.8).
Results: Among forty-five patients, 33 had loss while 12 had intact SMAD4. Loss of SMAD4 carries a 1.3 times increased risk of vascular and 1.6 times risk of nodal spread. Deletion of SMAD4 was associated with poor differentiation (p=0.04,OR=5.6,C.I=0.9-34.4), and increased the risk of perineural invasion by two times (OR=2,C.I=0.1-34.8).
Thirty-three, eighteen, and five patients survived at the end of 6, 12 and 24 months respectively. Analysis revealed statistically significant association between SMAD4 loss and survival at six months (p=0.04), 12 months (p=0.01) and 24 months (p=0.007). Among the operated patients (n=19), eleven patients developed recurrence during follow-up, period. all had loss of SMAD4 (p=0.03).
The hazard ratios for poor tumor differentiation and SMAD4 loss were 5.8 (95%C.I=1.2-28.4,p=0.02) and 6.7 (HR=6.7,95%C.I=1.9-23.3,p=0.002) respectively. The SMAD4 intact and loss group had median survival of 19.5+2.1 months (95%C.I=15.4-23.7) and 9.3+1.0 months (95%C.I=7.3-11.4) respectively, confers a survival advantage of 10 months (p=0.002,C.I.=-4.1to-0.9). Conclusion: Loss of SMAD4 is strongly associated with poor tumor differentiation with risk of metastasis at presentation. The overall survival is significantly influenced by the loss of SMAD4 and poor tumor differentiation.
EP02C-094 CIRCULATORY TUMOR CELLS OF PORTAL VENOUS SYSTEM IN CASE OF PANCREATIC CANCER AS A PREDICTIVE AND PROGNOSTIC INDICATOR OF METASTATIC PROGRESSION AND OVERALL SURVIVAL
S. Sapovalovs 1,2 , E. Miklasevics 1,2 , A. Pukitis 3,4 , M. Pavars 1 and J. Gardovskis 1,2 1 Surgery, Pauls Stradins Clinical University Hospital, 2 Rigas Stradins University, 3 Pauls Stradins Clinical University Hospital, and 4 University of Latvia, Latvia Background: Pancreatic cancer (PC) is one of most common, aggressive and potentially lethal oncological disease. PC builds up w3% of oncological burden and is a cause of mortality in 7% of cancer cases. Standard diagnostics of PC is CT, although in the last years endoscopic ultrasonography (EUS) is a helpful tool in management of small and borderline tumors. In situation of borderline cases more information should be acquired before the appropriate treatment is chosen. Nowadays "liquid biopsy" of the venous system can assist in circulatory tumor cell (CTC) verification in case of PC. The prognostic value of CTC is still investigated. Central blood samples are proved to be more informative and specific than peripheral. Methods: In a single-center cohort study 16 patients with suspected PC were evaluated. In all cases CT scan was done. Open laparotomy with or without pancreaticoduodenal resection was performed in 14 patients with acquisition of liquid biopsy from portal system. EUS guided transhepatic needle aspiration of portal vein was performed in 2 cases. Peripheral blood samples were obtained in both groups, sizes of the both samples were 10 mL.
Results: In 10 cases ductal adenocarcinoma was found in histological or cytological examination. In 3 cases neuroendocrine tumor was found. In another 3 cases pancreas cystadenoma was confirmed. Central and peripheral blood samples of 10 ductal adenocarcinoma cases were further analysed by InCell and NGS methods. In all cases positive liquid biopsy was verified. 9 out of 10 patients have died in 6 months after the surgery.
EP02C-095 18 FDG PET/CT IMPROVES STAGING OF SMALL £2 CM PANCREATIC TUMOURS E. Mohamed 1 , B. Sanghera 2 , W. Wong 2 , C. Halloran 1 and P. Ghaneh 1 1 Department of Molecular and Clinical Cancer Medicine, University of Liverpool, United Kingdom, and 2 East and North Hertfordshire NHS Trust, United Kingdom Introduction: Pancreatic cancer is a devastating disease with the highest survival figures currently achieved in patients with T1N0M0 disease. The aim of this study was to investigate whether 18 FDG PET/CT have an additional value for nodal and metastatic staging of small T1 tumours. Methods: We retrospectively screened the database of a clinical trial investigating the value of 18 FDG PET/CT in patients with suspected pancreatic cancer (PETPANC trial-ISRCTN73852054). Patients with small 2cm tumours were identified. Positive and negative influences of 18 FDG PET/CT acquisition over standardised staging with CT scan +/-MRCP +/-EUS on disease nodal and metastatic staging was gauged against a reference diagnosis after review of available histopathological findings and follow up data for up to 12 months following enrolment into the trial. Results: 65 patients with small tumours were identified. The median tumour size was 18mm with MRCP + EUS being employed in 18% and 17% of the cases respectively. For nodal staging, 18 FDG PET/CT had a positive influence in 14 patients (21.5%) with 10 patients correctly upstaged and 4 patients correctly down-staged while it had a negative influence in 3 patients (2 patients wrongly upstaged,1 wrongly down-staged) . As for the M stage, it influenced the management decisions of 5 patients (7.7%) with three of them identified to have occult distant metastasis not identified on CT while the other two had confirmed benign lesions rather than malignant on 18 FDG PET/CT. 
S560
Electronic Posters (EP02A-EP02F) e Pancreas
